Advertisement

Recombinant Protein Drugs

  • Peter Buckel

Part of the Milestones in Drug Therapy book series (MDT)

Table of contents

  1. Front Matter
    Pages I-X
  2. Pioneers and business

    1. Front Matter
      Pages 1-1
    2. Charles Weissmann
      Pages 3-41
  3. First generation proteins

    1. Front Matter
      Pages 65-65
    2. George G. Brownlee, Paul L. F. Giangrande
      Pages 67-88
    3. Karl Welte, Erich Platzer
      Pages 89-106
  4. Proteins with new functions: protein engineering

  5. Further improvement of protein drugs

    1. Front Matter
      Pages 149-149
  6. Back Matter
    Pages 181-207

About this book

Introduction

Recombinant protein drugs are intimately associated with the impressive success story of the Biotech Industry during the past thirty years, some of them belonging to the most successful pharmaceutical products. More than thirty different proteins are available for a variety of clinical applications, over 300 proteins are presently being evaluated in clinical trials. In this new volume of the MDT series, historical, technical and clinical aspects of recombinant protein drug discovery and development are presented, covering past, present and future highlights. Leading scientists and co-founders of early Biotech companies describe technical breakthroughs and the fascinating story of pioneering discoveries, as well as the long way of translating them into products and business. Therefore, this book represents an exciting documentation of the beginning of a new era in the pharmaceutical industry. In addition, scientists from basic research, clinic and industry actively involved in new developments discuss...

Keywords

clinic clinical trial development drug drug discovery drugs future gene therapy hepatitis interferon oncology pharmaceutical protein protein engineering research

Editors and affiliations

  • Peter Buckel
    • 1
  1. 1.Xantos BiomedicineMartinsriedGermany

Bibliographic information

Industry Sectors
Pharma
Health & Hospitals
Biotechnology